Article
Multidisciplinary Sciences
Shaheen A. Farhadi, Renjie Liu, Matthew W. Becker, Edward A. Phelps, Gregory A. Hudalla
Summary: Galectin-3 exhibits dynamic oligomerization and promiscuous binding, affecting cell behavior by influencing signaling pathways. Synthetic Gal3 constructs with defined valency can physically regulate extracellular signaling activity and cell death induction. Changes in multivalency impact caspase activation, membrane glycoprotein engagement, and intracellular pathway activation.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2021)
Article
Cardiac & Cardiovascular Systems
Pedro Caravaca Perez, Jose R. Gonzalez-Juanatey, Jorge Nuche, Lucia Matute-Blanco, Isabel Serrano, Manuel Martinez Selles, Rafael Vazquez Garcia, Luis Martinez Dolz, Manuel Gomez-Bueno, Domingo Pascual Figal, Maria G. Crespo-Leiro, Alvaro Garcia-Osuna, Jordi Ordonez-Llanos, Juan Cinca Cuscullola, Jose M. Guerra, Juan F. Delgado
Summary: This study investigated the relationship between the inflammatory marker Galectin-3 and renal function in patients with acute heart failure. The results showed that renal function influences the prognostic value of Galectin-3 levels in these patients.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2022)
Article
Pharmacology & Pharmacy
Xin Gu, Hongxue Meng, Jia Wang, Ruitao Wang, Muyang Cao, Siyu Liu, Hui Chen, Yangyang Xu
Summary: In renal cell carcinoma, the expression of galectin-3 and HIF-1α is significantly elevated, and hypoxia can further promote their expression. HIF-1α plays a critical role in the regulation of galectin-3 in RCC.
EUROPEAN JOURNAL OF PHARMACOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Ghulam Md Ashraf, Mohd Rehan, Alhuseen O. Alsayed, Pallavi Somvanshi, Shafiul Haque
Summary: This study examines the possibility of cardiovascular medications inhibiting Galectin-3-related biological activities using bioinformatics techniques. Through clustering, molecular docking, and molecular dynamics simulation, potential chemical compounds were screened and repurposed. The results show that certain compounds have the ability to inhibit Galectin-3. Further experimental validation and animal model-based studies are needed.
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
(2023)
Article
Biochemistry & Molecular Biology
Qingfeng Wu, Shiren Sun, Lei Wei, Minna Liu, Hao Liu, Ting Liu, Ying Zhou, Qing Jia, Di Wang, Zhen Yang, Menglu Duan, Xiaoxia Yang, Peisong Gao, Xiaoxuan Ning
Summary: This study reveals a significant association between Twist1 expression in macrophages and the severity of renal fibrosis in IgA nephropathy patients and mice with unilateral ureteral obstruction. Twist1 ablation in macrophages alleviates renal tubular injury and fibrosis, accompanied by reduced macrophage infiltration and M2 polarization in the kidney. Twist1 downregulation inhibits macrophage chemotaxis and migration, at least partially through the CCL2/CCR2 axis. This study highlights the regulation of macrophage plasticity through Twist1/galectin-3 signaling and its potential as a new strategy for delaying kidney fibrosis in chronic kidney disease patients.
CELLULAR AND MOLECULAR LIFE SCIENCES
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Octavia Bane, Daniela Said, Amanda Weiss, Daniel Stocker, Paul Kennedy, Stefanie J. Hectors, Rafael Khaim, Fadi Salem, Veronica Delaney, Madhav C. Menon, Michael Markl, Sara Lewis, Bachir Taouli
Summary: The study found that 4D flow parameters had good inter-observer reproducibility, especially in the renal artery (RA). The flow in RA and RV could distinguish between functional and dysfunctional allografts, and were correlated with histopathology.
EUROPEAN RADIOLOGY
(2021)
Article
Pharmacology & Pharmacy
Victoria Sundblad, Ramiro A. Gomez, Juan C. Stupirski, Pablo F. Hockl, Maria S. Pino, Hugo Laborde, Gabriel A. Rabinovich
Summary: Serum levels of Gal-3 are associated with clinical manifestations of systemic sclerosis, with a particular association with the presence of telangiectasias.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Peripheral Vascular Disease
Qi-Fang Huang, Yi-Bang Cheng, Qian-Hui Guo, Ying Wang, Yi-Lin Chen, Dong-Yan Zhang, De-Wei An, Yan Li, Ji-Guang Wang
Summary: This study investigated the independent association between serum galectin-3 and mucin-1 (CA15-3) and renal function in untreated Chinese patients with suspected hypertension. The results showed that both galectin-3 and mucin-1 (CA15-3) concentrations were significantly associated with eGFR. Additionally, the association between mucin-1 (CA15-3) concentration and eGFR was stronger in overweight and obese subjects. Serum galectin-3 might affect renal function partially through mucin-1.
AMERICAN JOURNAL OF HYPERTENSION
(2023)
Review
Biochemistry & Molecular Biology
Lucas de Freitas Pedrosa, Avraham Raz, Joao Paulo Fabi
Summary: The review focuses on revealing the structure/function relationship of pectins, their fragments, and their biological effects. The discussion highlights different effects described within in vitro and in vivo experimental models, with interesting and sometimes contradictory results, especially regarding galectin-3 interaction.
Article
Clinical Neurology
Yarong Ding, Liping Liu, Zimo Chen, Hao Li, Yuesong Pan, Junfeng Wang, Xia Meng, Jinxi Lin, Jing Jing, Xuewei Xie, Xianglong Xiang, Yongjun Wang
Summary: This study found a U-shaped correlation between serum CysC levels and 1-year stroke clinical outcomes in patients with acute ischemic stroke, suggesting that CysC may not only be a marker of renal function but also play a role in predicting cardiovascular events.
FRONTIERS IN NEUROLOGY
(2021)
Article
Surgery
Deirdre Sawinski, Liza Johannesson, Jakub Kristek, Jiri Fronek, Kathleen E. O'Neill, Anthony Gregg, Giuliano Testa, Paige M. Porrett
Summary: Uterus transplantation is an effective treatment for uterine factor infertility, but it carries the risk of immunosuppression and congenital renal anomalies. A study on UTx recipients found a decline in renal function starting at 30 days posttransplant and a high incidence of acute kidney injury and pre-eclampsia during pregnancy. Further research is needed to assess long-term renal risks for UTx recipients.
AMERICAN JOURNAL OF TRANSPLANTATION
(2022)
Article
Medicine, General & Internal
Chun-Yen Chiang, Sheng-Chung Huang, Michael Chen, Jhih-Yuan Shih, Chon-Seng Hong, Nan-Chun Wu, Chung-Han Ho, Chia Chun Wu, Zhih-Cherng Chen, Wei-Ting Chang
Summary: This study examined the impact of renal impairment on treatment, echocardiographic parameters, and outcomes in AMI patients undergoing PCI. Patients with worse renal function were older, had more comorbidities, received less guideline-directed therapy, and had poorer cardiovascular outcomes.
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
(2021)
Article
Clinical Neurology
Bo Hoon Lee, Stella Deng, Claudia A. Chiriboga, Denise M. Kay, Obehioya Irumudomon, Emma Laureta, Leslie Delfiner, Simona O. Treidler, Yaacov Anziska, Ai Sakonju, Chelsea Kois, Osman Farooq, Kristin Engelstad, Alexandra Laurenzano, Katherine Hogan, Michele Caggana, Carlos A. Saavedra-Matiz, Colleen F. Stevens, Emma Ciafaloni
Summary: Universal newborn screening for SMA in New York State started in October 2018, with nearly 650,000 infants screened in the first 3 years. The majority of infants who screened positive have received treatment, with a high percentage undergoing gene replacement therapy. Early clinical follow-up data showed clinically asymptomatic post-treatment outcomes in infants with 3 copies of SMN2. Factors contributing to delays in treatment included medical issues such as presence of AAV9 antibodies and nonmedical barriers like insurance policies.
Article
Biochemistry & Molecular Biology
Shuo-Ming Ou, Ming-Tsun Tsai, Huan-Yuan Chen, Fu-An Li, Kuo-Hua Lee, Wei-Cheng Tseng, Fu-Pang Chang, Yao-Ping Lin, Ruey-Bing Yang, Der-Cherng Tarng
Summary: Plasma galectin-3 is associated with organ fibrosis, and this study explored the potential of urinary galectin-3 as a biomarker for kidney disease progression. Patients with higher urinary galectin-3 levels had lower eGFRs and higher proteinuria levels. Higher levels of urinary galectin-3 were also associated with more severe renal fibrosis. The study suggests that urinary galectin-3 levels may be useful for identifying patients at high risk of kidney disease progression and renal fibrosis.
Article
Biochemistry & Molecular Biology
Teresa Peiro, Miriam Alonso-Carpio, Pilar Ribera, Patricia Almudever, Ines Roger, Paula Montero, Severiano Marin, Javier Milara, Julio Cortijo
Summary: This study investigates the role of GAL-3 in skin fibrosis and demonstrates its significantly increased expression using various models and techniques.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Cardiac & Cardiovascular Systems
S. N. Voorrips, E. M. Boorsma, J. C. Beusekamp, R. A. DE -boer, M. A. Connelly, R. P. F. Dullaart, P. Van-der-meer, D. J. Van-veldhuisen, A. A. Voors, K. Damman, B. D. Westenbrink
Summary: This study analyzed the ketone body production in patients with acute decompensated heart failure and found that ketone body concentrations were significantly increased during acute decompensation. However, treatment with empagliflozin had no significant effect on ketone body concentrations. These findings provide insights into the metabolic characteristics of acute heart failure.
JOURNAL OF CARDIAC FAILURE
(2023)
Article
Medicine, General & Internal
Navin Suthahar, Kan Wang, Victor W. Zwartkruis, Stephan J. L. Bakker, Silvio E. Inzucchi, Tim R. Eijgenraam, Fariba Ahmadizar, Eric G. Sijbrands, Ron T. Gansevoort, Lyanne M. Kieneker, Dirk J. van Veldhuisen, Maryam Kavousi, Rudolf A. de Boer
Summary: Relative fat mass (RFM), a novel anthropometric equation based on height and waist measurements, is strongly associated with incident type-2 diabetes (T2D) and shows potential as a predictor of future diabetes risk in the general population, outperforming BMI, waist circumference, and waist-to-hip ratio.
EUROPEAN JOURNAL OF INTERNAL MEDICINE
(2023)
Article
Cardiac & Cardiovascular Systems
Jawad H. Butt, Kieran F. Docherty, Brian L. Claggett, Akshay S. Desai, James C. Fang, Magnus Petersson, Anna Maria Langkilde, Rudolf A. de Boer, Jose Walter Cabrera Honorio, Adrian F. Hernandez, Silvio E. Inzucchi, Mikhail N. Kosiborod, Lars Kober, Carolyn S. P. Lam, Felipe A. Martinez, Piotr Ponikowski, Marc S. Sabatine, Orly Vardeny, Eileen O'Meara, Jose F. K. Saraiva, Sanjiv J. Shah, Muthiah Vaduganathan, Pardeep S. Jhund, Scott D. Solomon, John J. V. McMurray
Summary: Black people have a higher incidence and prevalence of heart failure than White people, and they may have worse outcomes once HF has developed. This study examined the outcomes and response to treatment with dapagliflozin in Black and White patients with heart failure. The results showed that dapagliflozin had consistent benefits in both Black and White patients, with greater absolute benefits in Black patients.
JACC-HEART FAILURE
(2023)
Article
Cardiac & Cardiovascular Systems
Guenther Silbernagel, Yan Q. Chen, Martin Rief, Marcus E. Kleber, Michael M. Hoffmann, Tatjana Stojakovic, Andreas Stang, Mark A. Sarzynski, Claude Bouchard, Winfried Maerz, Yue-Wei Qian, Hubert Scharnagl, Robert J. Konrad
Summary: Apolipoprotein C-II (ApoC-II) has an inverse J-shaped relationship with cardiovascular mortality, with the lowest risk observed in the middle quintile. Increasing low circulating ApoC-II levels may reduce cardiovascular risk.
EUROPEAN HEART JOURNAL
(2023)
Article
Cardiac & Cardiovascular Systems
Safia Chatur, Muthiah Vaduganathan, Brian Claggett, Orly Vardeny, Akshay S. Desai, Pardeep S. Jhund, Rudolf A. de Boer, Carolyn S. P. Lam, Mikhail N. Kosiborod, Sanjiv J. Shah, Felipe Martinez, Silvio E. Inzucchi, Adrian F. Hernandez, Tariq Haddad, Sumeet S. Mitter, Zi Michael Miao, Magnus Petersson, Anna Maria Langkilde, John J. McMurray, Scott D. Solomon
Summary: In this study, the safety and efficacy of dapagliflozin were evaluated according to different diuretic therapies and its influence on diuretic use. The results showed that dapagliflozin had consistent clinical benefits in terms of reducing heart failure worsening and cardiovascular death across different diuretic categories and doses, with a similar safety profile. Dapagliflozin also significantly reduced the need for loop diuretics over time.
EUROPEAN HEART JOURNAL
(2023)
Article
Cardiac & Cardiovascular Systems
Ankeet S. Bhatt, Mikhail N. Kosiborod, Muthiah Vaduganathan, Brian L. Claggett, Z. Michael Miao, Ian J. Kulac, Carolyn S. P. Lam, Adrian F. Hernandez, Felipe Martinez, Silvio E. Inzucchi, Sanjiv J. J. Shah, Rudolf A. de Boer, Pardeep S. Jhund, Akshay S. Desai, Magnus Petersson, Anna Maria Langkilde, John J. V. McMurray, Scott D. Solomon
Summary: In this study, the effects of dapagliflozin on health status in heart failure patients were examined. The results showed that dapagliflozin improved health status in patients across the full range of left ventricular ejection fraction (LVEF).
EUROPEAN JOURNAL OF HEART FAILURE
(2023)
Article
Cardiac & Cardiovascular Systems
Safia Chatur, Jonathan W. Cunningham, Muthiah Vaduganathan, Finnian R. Mc Causland, Brian L. Claggett, Akshay S. Desai, Zi Michael Miao, Pardeep S. Jhund, Rudolf A. de Boer, Adrian F. Hernandez, Silvio E. Inzucchi, Mikhail N. Kosiborod, Carolyn S. P. Lam, Felipe A. Martinez, Sanjiv J. Shah, Magnus Petersson, Anna Maria Langkilde, John J. V. McMurray, Scott D. Solomon
Summary: In patients recently hospitalized for heart failure, dapagliflozin can reduce the risk of hospitalization and has minimal effects on blood pressure and renal function. It is a safe and effective treatment option for stabilized patients with heart failure.
EUROPEAN JOURNAL OF HEART FAILURE
(2023)
Article
Cardiac & Cardiovascular Systems
Mark Jansen, A. F. Schmidt, J. J. M. Jans, I. Christiaans, S. N. van der Crabben, Y. M. Hoedemaekers, D. Dooijes, J. D. H. Jongbloed, L. G. Boven, R. H. Lekanne Deprez, A. A. M. Wilde, J. van der Velden, R. A. de Boer, J. P. van Tintelen, F. W. Asselbergs, A. F. Baas
Summary: In this study, acylcarnitines were evaluated as potential biomarkers for hypertrophic cardiomyopathy (HCM). The study found that several acylcarnitines were significantly increased in patients with severe HCM, and some were also increased in patients with mild HCM. Additionally, certain acylcarnitines were associated with measures of HCM severity. Prospective studies are needed to further investigate the prognostic value of these biomarkers.
JOURNAL OF CARDIOVASCULAR TRANSLATIONAL RESEARCH
(2023)
Review
Oncology
Laura I. Yousif, Elles M. Screever, Danielle Versluis, Joseph Pierre Aboumsallem, Stefan Nierkens, Olivier C. Manintveld, Rudolf A. de Boer, Wouter C. Meijers
Summary: This review discusses the four main risk factors for immune checkpoint inhibitor-related cardiovascular adverse events (irAEs), including ICI combination therapy, combination with other anti-cancer treatments, female sex, pre-existing cardiovascular disease, and specific tumors. An a priori risk strategy is needed to determine who is at risk for developing these cardiovascular irAEs, and a better understanding of the impact of risk factors is crucial for improving care and disease management in these patients.
CURRENT ONCOLOGY REPORTS
(2023)
Article
Cardiac & Cardiovascular Systems
Ali A. A. Al-Mubarak, Niels Grote Beverborg, Victor Zwartkruis, Colinda van Deutekom, Martin H. H. de Borst, Ron T. T. Gansevoort, Stephan J. L. Bakker, Daan J. J. Touw, Rudolf A. A. de Boer, Peter van der Meer, Michiel Rienstra, Nils Bomer
Summary: This study aimed to investigate the association between micronutrient deficiencies and the development of atrial fibrillation (AFib). Selenium deficiency was found to be associated with new-onset AFib in non-smoking participants.
CLINICAL RESEARCH IN CARDIOLOGY
(2023)
Article
Cardiac & Cardiovascular Systems
Elena Arbelo, Alexandros Protonotarios, Juan R. Gimeno, Eloisa Arbustini, Roberto Barriales-Villa, Cristina Basso, Connie R. Bezzina, Elena Biagini, Nico A. Blom, Rudolf A. de Boer, Tim De Winter, Perry M. Elliott, Marcus Flather, Pablo Garcia-Pavia, Kristina H. Haugaa, Jodie Ingles, Ruxandra Oana Jurcut, Sabine Klaassen, Giuseppe Limongelli, Bart Loeys, Jens Mogensen, Iacopo Olivotto, Antonis Pantazis, Sanjay Sharma, J. Peter Van Tintelen, James S. Ware, Juan Pablo Kaski
EUROPEAN HEART JOURNAL
(2023)
Meeting Abstract
Cardiac & Cardiovascular Systems
L. M. G. Laura Marieke Gezina Meems, S. Li, G. Krenning, C. J. Boogerd, H. H. W. Sillje, C. Withaar, R. A. De Boer
EUROPEAN JOURNAL OF HEART FAILURE
(2023)
Meeting Abstract
Cardiac & Cardiovascular Systems
Peikert, P. Goyal, M. Vaduganathan, B. L. Claggett, A. S. Desai, P. S. Jhund, M. N. Kosiborod, C. S. P. Lam, S. E. Inzucchi, F. A Martinez, R. A. De Boer, A. F. Hernandez, S. J. Shah, J. J. V. Mcmurray, S. D. Solomon
EUROPEAN JOURNAL OF HEART FAILURE
(2023)
Meeting Abstract
Cardiac & Cardiovascular Systems
T. B. Petersen, N. Suthahar, F. W. Asselbergs, M. De Bakker, K. M. Akkerhuis, A. A. Constantinescu, J. Van Ramshorst, P. D. Katsikis, P. J. Van Der Spek, V. A. Umans, R. A. De Boer, E. Boersma, D. Rizopoulos, I. Kardys
EUROPEAN JOURNAL OF HEART FAILURE
(2023)
Meeting Abstract
Cardiac & Cardiovascular Systems
N. T. B. Niels Tjeerd Benjamin Scholte, M. T. Gurgoze, D. Aydin, D. A. M. J. Theuns, O. C. Manintveld, E. Ronner, E. Boersma, R. A. De Boer, R. M. A. Van der Boon, J. J. Brugts
EUROPEAN JOURNAL OF HEART FAILURE
(2023)